N-Zyme Biotec

N-Zyme Biotec is pioneering a novel therapeutic approach for laryngopharyngeal reflux (LPR), a prevalent condition with no approved effective drug therapy. The company's core strategy involves the drug repurposing of fosamprenavir, a known HIV protease inhibitor, to inhibit pepsin—the key enzyme believed to cause tissue damage in LPR. With a Phase III clinical trial approved by the FDA and a strengthening intellectual property portfolio, N-Zyme is advancing a dual-formulation strategy (oral and inhaled) to address a significant unmet medical need affecting an estimated 10-30% of the U.S. population.

Drug repurposing and reformulation platform focused on pepsin inhibition for reflux diseases. Utilizes known HIV protease inhibitors (e.g., fosamprenavir) and develops novel delivery systems (sustained-release oral, dry powder inhaler) for localized treatment.

N-Zyme's approach is first-in-class, with no direct competitors developing a targeted pepsin inhibitor. Indirect competition includes over-the-counter antacids, prescription proton pump inhibitors (PPIs), and H2 blockers, which are often ineffective for LPR. Surgical fundoplication is an invasive option for severe cases but is not a pharmacological solution.